目的 探討清開靈注射液聯(lián)合丁苯酞治療急性腦梗死的臨床療效。方法 選取2022年12月—2023年12月秦皇島市工人醫(yī)院收治的88例急性腦梗死患者，按隨機數(shù)字表法將患者分為對照組和治療組，每組各44例。對照組靜脈滴注丁苯酞氯化鈉注射液，100 mL/次，滴注時間≥50 min/次，2次/d。治療組在對照組治療基礎(chǔ)上靜脈滴注清開靈注射液，40 mL加入生理鹽水250 mL中充分稀釋，1次/d。兩組療程14 d。觀察兩組臨床療效，比較兩組治療前后情緒和社會功能障礙量表（ESDQ）評分、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、凝血酶–抗凝血酶復(fù)合物（TAT）、血小板參數(shù)[血小板平均體積（MPV）、血小板聚集率（PAgT）]及血清同型半胱氨酸（Hcy）、C反應(yīng)蛋白（CRP）、超氧化物歧化酶（SOD）、神經(jīng)元特異性烯醇化酶（NSE）水平。結(jié)果 治療后，治療組總有效率是95.45%，顯著高于對照組的81.82%（P＜0.05）。治療后，兩組ESDQ評分、NIHSS評分均顯著降低（P＜0.05）；治療后，治療組ESDQ評分、NIHSS評分低于對照組（P＜0.05）。治療后，兩組TAT和血小板參數(shù)MPV、PagT均較同組治療前顯著降低（P＜0.05）；治療后，治療組TAT、MPV、PagT低于對照組（P＜0.05）。治療后，兩組血清Hcy、CRP、NSE水平均顯著降低，而血清SOD水平均顯著上升（P＜0.05）；治療后，治療組血清Hcy、CRP、SOD、NSE水平改善優(yōu)于對照組（P＜0.05）。結(jié)論 清開靈注射液聯(lián)合丁苯酞治療急性腦梗死具有較好的臨床療效，能有效抗血栓形成、緩解炎癥和氧化應(yīng)激損害，保護神經(jīng)元，促進患者神經(jīng)功能、情緒和社會功能障礙恢復(fù)。

Objective To investigate the clinical effect of Qingkailing Injection combined with butylphthalein in treatment of acute cerebral infarction. Methods A total of 88 patients with acute cerebral infarction admitted to Qinhuangdao Workers’ Hospital from December 2022 to December 2023 were divided into control group and treatment group according to random number table method, with 44 cases in each group. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 100 mL/time, infusion time ≥ 50 min/time, twice daily. Patients in the treatment group were iv administered with Qingkailing Injection on the basis of the control group, 40 mL was added to normal saline 250 mL and dilute fully, once daily. Both groups were treated for 14 d. The clinical effect of the two groups was observed, and the changes of Mood and Social Dysfunction Scale (ESDQ) score, National Institutes of Health Stroke Scale (NIHSS) score, thrombin-antithrombase complex (TAT), platelet parameters [mean platelet volume (MPV), platelet aggregation rate (PAgT)], serum homocysteine (Hcy), C-reactive egg before and after treatment White (CRP), superoxide dismutase (SOD), neuron-specific enolase (NSE) in two groups before and after treatment were compared.Results After treatment, the total effective rate of the treatment group was 95.45%, which was significantly higher than that of the control group (81.82%, P < 0.05). After treatment, ESDQ score and NIHSS score were significantly decreased in both groups (P < 0.05). After treatment, ESDQ scores and NIHSS scores in the treatment group were lower than those in the control group (P < 0.05). After treatment, TAT and platelet parameters MPV and PagT in two groups were significantly decreased compared with before treatment (P < 0.05). After treatment, TAT, MPV and PagT in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of serum Hcy, CRP and NSE were significantly decreased, but the levels of serum SOD were significantly increased in both groups (P < 0.05). After treatment, the levels of Hcy, CRP, SOD and NSE in the treatment group were better than those in the control group (P < 0.05). Conclusion Qingkailing Injection combined with butylphthalein has good clinical efficacy in treatment of acute cerebral infarction, and can effectively anti-thrombosis, relieve inflammation and oxidative stress damage, protect neurons, and promote the recovery of neurological, emotional and social dysfunction in patients.

R971